White House Mulling Potential Yellen Departure after Midterms

-Axios https://www.axios.com/2022/09/28/janet-yellen-treasury-midterms-shuffle

byCharles Gross

September 27, 2022

1 minute read

-Axios

https://www.axios.com/2022/09/28/janet-yellen-treasury-midterms-shuffle

Tech Innovation To Solve EV Challenges

By Upwallstreet

June 14, 2:36 PM

Tesla Inc (NASDAQ: TSLA) got the lead on the EV front as a pioneer with Elon Musk’s visionary leadership. But regulatory challenges, competition and an unfavorable macroeconomic environment made the ambitious Tesla focus on making an affordable vehicle while autonomous driving remains work in progress.

Jefferies Downgrades UroGen Pharma to Hold, Lowers Price Target to $10

By Benzinga Newsdesk

February 8, 6:18 AM

Jefferies analyst Chris Howerton downgrades UroGen Pharma (NASDAQ:URGN) from Buy to Hold and lowers the price target from $35 to $10.

URGN

Credit Suisse Maintains Outperform on Encompass Health, Lowers Price Target to $62

By Benzinga Newsdesk

September 21, 7:18 AM

Credit Suisse analyst A.J. Rice maintains Encompass Health (NYSE:EHC) with a Outperform and lowers the price target from $63 to $62.

EHC

Knight-Swift Transportation Holdings Tightens FY23 Adj. EPS Guidance From $2.10-$2.30 To $2.10-$2.20 Vs $2.07 Est.

By Happy Mohamed

October 19, 4:22 PM

Guidance — We now expect that Adjusted EPS1 for full-year 2023 will range from $2.10 to 2.20. This is an update from our previously disclosed range of $2.10 to $2.30. Our expected Adjusted EPS1 range is based on

KNX

White House Mulling Potential Yellen Departure after Midterms

Related Posts

Tech Innovation To Solve EV Challenges

Jefferies Downgrades UroGen Pharma to Hold, Lowers Price Target to $10

Credit Suisse Maintains Outperform on Encompass Health, Lowers Price Target to $62

Knight-Swift Transportation Holdings Tightens FY23 Adj. EPS Guidance From $2.10-$2.30 To $2.10-$2.20 Vs $2.07 Est.